MaxCyte (MXCT) Peer Comparison

$1.22

$-0.06 (-4.69%)

As on 28-Aug-2026 16:01EDT

Market cap

$126 Mln

Revenue (TTM)

$31 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	126	12,753	10,906	9,948	9,762
Revenue ($ Mln)	31	1,505	613	785	2,589
Net Profit ($ Mln)	-35.64	160.59	-188.05	41.54	222.40
Net Margin (%)	-114.77	10.67	-30.68	5.29	8.59
RoE (%)	-21.58	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	0.83	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	31.05	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	6.39	483.98	127.96	384.30	1,245.50
Gross Profit	26.80	942.44	393.22	347.62	1,343.60
Operating Expenses	59.33	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-34.66	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-35.64	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-35.64	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	158.75	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	16.03	210.18	135.71	705.49	2,116.80
Current Liabilities	9.90	233.78	102.33	132.66	961.30
Total Liabilities	202.51	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	63.40	630.60	404.74	1,749.63	7,231.50
Current Assets	121.27	1,344.12	515.78	1,200.55	3,020.50
Total Assets	202.51	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	17.25	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-34.41	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	25.94	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	0.66	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-21.58	11.76	-22.53	1.79	8.98
ROE (%)	-21.58	10.86	-28.10	1.97	3.04
ROA (%)	-13.27	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-86.19	13.63	-30.58	9.87	-5.99
Net Margin (%)	-114.77	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	-13.15	17.55	41.55	16.49	1.37
EBIT Growth (%)	40.23	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	20.41	8.72	-102.66	400.42	-30.32
EPS Growth (%)	21.12	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-17.09	17.33	-12.65	2.16	2.19

Valuation Ratios

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-3.70	68.93	-34.59	189.42	--
Price / Book Value	0.83	8.58	9.90	4.86	--
Dividend Yield (%)	0.00	--	--	0.00	--
EV/EBITDA	-1.26	53.25	-43.50	81.02	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.01	0.01	0.00	0.01	0.06
Current Ratio	12.26	5.75	5.04	9.05	3.14
Quick Ratio	11.47	3.86	4.46	7.64	2.33
Interest Coverage	--	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	MaxCyte (MXCT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	12.63	12.65	22.67	20.09	17.06
Asset Turnover	0.12	0.74	0.59	0.26	0.24
Receivable days	45.26	46.54	60.95	72.41	65.39
Inventory Days	483.15	331.92	193.84	146.53	221.09
Payable days	80.98	26.16	60.19	29.05	37.02
Cash Conversion Cycle	447.44	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly